ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Rated Buy in New Coverage at Compass Point

Equities researchers at Compass Point started coverage on shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) in a research report issued to clients and investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Compass Point’s price target points to a potential upside of 55.76% from the company’s current price.

CHRN has been the topic of several other research reports. Northland Securities started coverage on shares of ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They set an “outperform” rating and a $32.00 price target on the stock. Weiss Ratings raised ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 9th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $21.00.

ChronoScale Corporation Common Stock Trading Up 7.9%

NASDAQ CHRN opened at $16.05 on Friday. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -2.98 and a beta of 0.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 0.51 and a quick ratio of 0.51. ChronoScale Corporation Common Stock has a 12 month low of $3.50 and a 12 month high of $30.00. The company’s fifty day moving average price is $19.90 and its two-hundred day moving average price is $18.19.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its earnings results on Wednesday, October 14th. The company reported ($0.29) earnings per share for the quarter. The company had revenue of $41.48 million during the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc boosted its holdings in ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,338 shares of the company’s stock after purchasing an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned approximately 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent quarter. 6.42% of the stock is owned by institutional investors and hedge funds.

Key ChronoScale Corporation Common Stock News

Here are the key news stories impacting ChronoScale Corporation Common Stock this week:

• Positive Sentiment: Northland maintains “Outperform” rating: Northland Securities kept its $32 target price, substantially above the stock’s recent trading level, indicating confidence in ChronoScale’s longer-term growth prospects. The analyst projects a return to quarterly profitability in Q4 2028, with estimated EPS of $0.16. Northland analyst estimates
• Positive Sentiment: Revenue reached $41.48 million: ChronoScale’s fiscal first-quarter results provide investors with evidence of commercial activity as the company develops its accelerated-computing platform for artificial-intelligence workloads. ChronoScale fiscal first-quarter results
• Neutral Sentiment: Analyst forecasts remain focused on future improvement: Northland estimates losses of $0.39 per share for fiscal 2027 and $0.15 per share for fiscal 2028, with projected quarterly losses through Q3 2028 before the expected Q4 2028 profit. This suggests a lengthy path to sustainable earnings.
• Negative Sentiment: Current profitability remains weak: ChronoScale reported a fiscal first-quarter loss of $0.29 per share, alongside a negative net margin of 135.66% and negative return on equity of 197.81%. Its 0.51 current and quick ratios also point to limited near-term liquidity, factors that may weigh on the stock despite the bullish price target. ChronoScale earnings snapshot

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.